First clinical studies on mabuterol. A summarizing report.
In a dose finding study, a total of 245 asthmatic patients were given a single dose of 30, 40, 50, 60, 70 and 80 micrograms of dl-1-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butylamino-etha nol hydrochloride (mabuterol). From the results, 50 micrograms of mabuterol proved to be the optimal single dose in terms of effectiveness and tolerability. In a multicenter comparative study, asthmatic patients were treated with 50 or 75 micrograms of mabuterol twice a day for 6 weeks. From the results, 50 micrograms of mabuterol twice a day proved to be optimally effective and tolerable.